MetabolicEmerging Evidence

Survodutide

Also known as: BI 456906, Glucagon/GLP-1 dual agonist

Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Evidence

Emerging

FDA status

Not FDA-approved

Source

Synthetic glucagon/GLP-1 dual agonist

Overview

Investigational dual glucagon and GLP-1 receptor agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH).

Mechanism of Action

Dual agonist of glucagon and GLP-1 receptors, increases energy expenditure and fat oxidation via glucagon pathway, reduces appetite and improves insulin secretion via GLP-1, targets liver fat reduction and metabolic health.

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Weight loss (trials)
  • Liver fat (trials)
  • Increases energy expenditure
  • Improved metabolic parameters
  • Appetite suppression
  • Liver scarring (trials)

Researched for

Research topics, not approved uses.

Obesity (investigational)MASH/NAFLD (investigational)Metabolic syndromeType 2 diabetes

How Gabriel approaches peptides

Through Gabriel, licensed clinicians may prescribe BPC-157, TB-500, MOTS-c, epitalon and semax (nasal) as compounded medications from licensed 503A pharmacies, under HHS's October 28, 2026 interim policy, and only when appropriate. They are not FDA-approved, and Gabriel never gives peptide dosing. Survodutide isn't prescribed through Gabriel. If you're thinking about it, Gabriel can help you find a licensed clinician to look at the cause of what you're dealing with and the options with stronger evidence.

Read the peptide therapy guide

Research & Evidence

Evidence Level
Emerging
Studies

Phase 2 trials for obesity and MASH

Summary

Phase 2 and phase 3 trials reported weight loss and lower liver fat. As of October 2026 it is not FDA-approved.

Safety Information

Potential Side Effects

  • •Nausea
  • •Diarrhea
  • •Vomiting
  • •Injection site reactions
  • •Elevated heart rate (mild)

Contraindications

  • Under investigation

Interactions

  • ⚠Under investigation

Quick Facts

CategoryMetabolic
SourceSynthetic glucagon/GLP-1 dual agonist
StatusInvestigational; not FDA-approved (as of October 2026)